Interplay between CMVs and interferon signaling: Implications for pathogenesis and therapeutic intervention

Future Microbiology

Volumn 7, Issue 11, 2012, Pages 1269-1282

  Trilling, Mirko ^a,b   Le, Vu Thuy Khanh ^a   Hengel, Hartmut ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

herpesvirus; antiviral; cytomegalovirus; HCMV; HHV 5; immune evasive; interferon; JAK STAT signaling

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ALPHA2C INTERFERON; BETA INTERFERON; BETA INTERFERON RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INFLUENZA VACCINE; INTERFERON; JANUS KINASE 1; JANUS KINASE 2; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEASOME INHIBITOR; PROTEIN KINASE TYK2; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RETINOIC ACID INDUCIBLE PROTEIN I; RIBAVIRIN; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; AUTOCRINE EFFECT; CELLULAR IMMUNITY; CHILDHOOD; CHRONIC GRANULOMATOUS DISEASE; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; ENHANCER REGION; GRAFT FAILURE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOCOMPETENCE; KAPOSI SARCOMA; LATENT VIRUS INFECTION; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; MOLECULAR EVOLUTION; MULTIPLE SCLEROSIS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SUPERINFECTION; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS MUTANT; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS PNEUMONIA; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INTERFERONS; MICE; SIGNAL TRANSDUCTION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84867715375     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.109     Document Type: Review

References (111)

1. Hengel H, Koszinowski UH, Conzelmann KK. Viruses know it all: New insights into IFN networks. Trends Immunol. 26, 396-401 (2005).
2. Marshall EE, Geballe AP. Multifaceted evasion of the interferon response by cytomegalovirus. J. Interferon Cytokine Res. 29, 609-619 (2009).
3. Trilling M, Hengel H. Cytomegaloviruses and interferons. In:Cytomegaloviruses: From Molecular Pathogenesis to Intervention, Volume I. Reddehase MJ (Ed.). Caister Academic Press, UK (2012) (In press).
4. Verma S, Benedict CA. Sources and signals regulating type I interferon production: Lessons learned from cytomegalovirus. J. Interferon Cytokine Res. 31, 211-218 (2011).
5. Varnum SM, Streblow DN, Monroe ME et al. Identification of proteins in human cytomegalovirus (HCMV) particles: The HCMV proteome. J. Virol. 78, 10960-10966 (2004).
6. Terhune SS, Schroer J, Shenk T. RNAs are packaged into human cytomegalovirus virions in proportion to their intracellular concentration. J. Virol. 78, 10390-10398 (2004).
7. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110, 937-945 (2007).
8. Kurz S, Steffens HP, Mayer A, Harris JR, Reddehase MJ. Latency versus persistence or intermittent recurrences: Evidence for a latent state of murine cytomegalovirus in the lungs. J. Virol. 71, 2980-2987 (1997).
9. Enders G, Daiminger A, Lindemann L et al. Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010. Med. Microbiol. Immunol. 201(3), 303-309 (2012).
10. Mustakangas P, Sarna S, Ammala P, Muttilainen M, Koskela P, Koskiniemi M. Human cytomegalovirus seroprevalence in three socioeconomically different urban areas during the first trimester: A population-based cohort study. Int. J. Epidemiol. 29, 587-591 (2000).
11. Ludwig A, Hengel H. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill. 14, 26-32 (2009).
12. Bristow BN, O'Keefe KA, Shafir SC, Sorvillo FJ. Congenital cytomegalovirus mortality in the United States, 1990-2006. Plos Negl. Trop. Dis. 5, e1140 (2011).
13. Ross SA, Fowler KB, Ashrith G et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J. Pediatr. 148, 332-336 (2006).
14. Iwasenko JM, Howard J, Arbuckle S et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J. Infect. Dis. 203, 1526-1533 (2011).
15. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review. Virol. J. 5, 47 (2008).
16. Polic B, Hengel H, Krmpotic A et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J. Exp. Med. 188, 1047-1054 (1998).
17. Karrer U, Sierro S, Wagner M et al. Memory inflation:Continuous accumulation of antiviral CD8+ T cells over time. J. Immunol. 170, 2022-2029 (2003).
18. Snyder CM, Cho KS, Bonnett EL, Allan JE, Hill AB. Sustained CD8+ T cell memory inflation after infection with a single-cycle cytomegalovirus. Plos Pathog. 7, e1002295 (2011).
19. Hansen SG, Powers CJ, Richards R et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328, 102-106 (2010
20. Hengel H, Koszinowski UH. Virology. A vaccine monkey wrench? Science 328, 51-52 (2010).
21. Waterston RH, Lindblad-Toh K, Birney E et al. Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520-562 (2002).
22. Medearis DN Jr. Mouse cytomegalovirus infection. 3. Attempts to produce intrauterine infections. Am. J. Hyg. 80, 113-120 (1964).
23. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77 (2003).
24. Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 129, 1111-1123 (2007).
25. Ndubuisi MI, Guo GG, Fried VA, Etlinger JD, Sehgal PB. Cellular physiology of STAT3: where's the cytoplasmic monomer? J. Biol. Chem. 274, 25499-25509 (1999).
26. Wenta N, Strauss H, Meyer S, Vinkemeier U. Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc. Natl Acad. Sci. USA 105, 9238-9243 (2008).
27. Meyer T, Marg A, Lemke P, Wiesner B, Vinkemeier U. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. Genes Dev. 17, 1992-2005 (2003).
28. Grandvaux N, Servant MJ, tenOever B et al. Transcriptional profiling of interferon regulatory factor 3 target genes: Direct involvement in the regulation of interferonstimulated genes. J. Virol. 76, 5532-5539 (2002).
29. Peters KL, Smith HL, Stark GR, Sen GC. IRF-3-dependent, NFkappa B- And JNK-independent activation of the 561 and IFN-beta genes in response to doublestranded RNA. Proc. Natl Acad. Sci. USA 99, 6322-6327 (2002).
30. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258-267 (1957
31. Glasgow LA, Hanshaw JB, Merigan TC, Petralli JK. Interferon and cytomegalovirus in vivo and in vitro. Proc. Soc. Exp. Biol. Med. 125, 843-849 (1967).
32. Le VT, Trilling M, Wilborn M, Hengel H, Zimmermann A. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol. 89, 2416-2426 (2008).
33. Zimmermann A, Trilling M, Wagner M et al. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-gamma signaling and antiviral responses. J. Exp. Med. 201, 1543-1553 (2005).
34. Sainz B Jr, LaMarca HL, Garry RF, Morris CA. Synergistic inhibition of human cytomegalovirus replication by interferonalpha/ beta and interferon-gamma. Virol. J. 2, 14 (2005).
35. Yamamoto N, Shimokata K, Maeno K, Nishiyama Y. Effect of recombinant human interferon gamma against human cytomegalovirus. Arch. Virol. 94, 323-329 (1987).
36. Matsumoto M, Tanaka N, Harada H et al. Activation of the transcription factor ISGF3 by interferon-gamma. Biol. Chem. 380, 699-703 (1999).
37. Lehtonen A, Matikainen S, Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J. Immunol. 159, 794-803 (1997).
38. Zhou A, Chen Z, Rummage JA et al. Exogenous interferon-gamma induces endogenous synthesis of interferon-alpha and -beta by murine macrophages for induction of nitric oxide synthase. J. Interferon Cytokine Res. 15, 897-904 (1995).
39. Pine R, Canova A, Schindler C. Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene. EMBO J. 13, 158-167 (1994).
40. Decker T, Lew DJ, Darnell JE Jr. Two distinct alpha-interferon-dependent signal transduction pathways may contribute to activation of transcription of the guanylatebinding protein gene. Mol. Cell Biol. 11, 5147-5153 (1991).
41. Hengel H, Lucin P, Jonjic S, Ruppert T, Koszinowski UH. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J. Virol. 68, 289-297 (1994).
42. Hengel H, Esslinger C, Pool J, Goulmy E, Koszinowski UH. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirusinfected cells. J. Gen. Virol. 76(Pt 12), 2987-2997 (1995).
43. Kropp KA, Robertson KA, Sing G et al. Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-gamma) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state. J. Virol. 85, 10286-10299 (2011).
44. Ishii KJ, Kawagoe T, Koyama S et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451, 725-729 (2008).
45. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GR. Transcriptional and posttranscriptional regulation of interferoninduced gene expression in human cells. Cell 38, 745-755 (1984).
46. Le VT, Trilling M, Zimmermann A, Hengel H. Mouse cytomegalovirus inhibits beta interferon (IFN-beta) gene expression and controls activation pathways of the IFN-beta enhanceosome. J. Gen. Virol. 89, 1131-1141 (2008).
47. Haagmans BL, van der Meide PH, Stals FS et al. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon. J. Virol. 68, 2305-2312 (1994).
48. Broering R, Zhang X, Kottilil S et al. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut 59, 1111-1119 (2010).
49. Ku CC, Che XB, Reichelt M et al. Herpes simplex virus-1 induces expression of a novel MxA isoform that enhances viral replication. Immunol. Cell Biol. 89, 173-182 (2011).
50. Schoggins JW, Wilson SJ, Panis M et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485 (2011).
51. Knoblach T, Grandel B, Seiler J, Nevels M, Paulus C. Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-gamma. Plos Pathog. 7, e1002016 (2011).
52. Netterwald J, Yang S, Wang W et al. Two gamma interferon-activated site-like elements in the human cytomegalovirus major immediate-early promoter/enhancer are important for viral replication. J. Virol. 79, 5035-5046 (2005).
53. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl Acad. Sci. USA 95, 3937-3942 (1998).
54. Presti RM, Pollock JL, Dal Canto AJ, O'Guin AK, Virgin HW. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 188, 577-588 (1998).
55. Gil MP, Bohn E, O'Guin AK et al. Biologic consequences of Stat1-independent IFN signaling. Proc. Natl Acad. Sci. USA 98, 6680-6685 (2001).
56. Strobl B, Bubic I, Bruns U et al. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J. Immunol. 175, 4000-4008 (2005).
57. Essers MA, Offner S, Blanco-Bose WE et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458, 904-908 (2009).
58. Banks TA, Rickert S, Benedict CA et al. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J. Immunol. 174, 7217-7225 (2005).
59. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 36, 515-528 (2012
60. Cunningham JA, Kellner JD, Bridge PJ, Trevenen CL, Mcleod DR, Davies HD. Disseminated bacille Calmette-Guerin infection in an infant with a novel deletion in the interferon-gamma receptor gene. Int. J. Tuberc. Lung Dis. 4, 791-794 (2000).
61. Vairo D, Tassone L, Tabellini G et al. Severe impairment of IFN-gamma and IFN-alpha responses in cells of a patient with a novel STAT1 splicing mutation. Blood 118, 1806-1817 (2011).
62. Stagno S, Pass RF, Cloud G et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256, 1904-1908 (1986).
63. Herman M, Ciancanelli M, Ou YH et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 209, 1567-1582 (2012).
64. Trilling M, Le VT, Zimmermann A et al. Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts. J. Virol. 83, 3684-3695 (2009).
65. Jonjic S, Pavic I, Polic B, Crnkovic I, Lucin P, Koszinowski UH. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179, 1713-1717 (1994).
66. Reinhard H, Le VT, Ohlin M, Hengel H, Trilling M. Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. Plos One 6, e14532 (2011).
67. Presti RM, Popkin DL, Connick M, Paetzold S, Virgin HW. Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages. J. Exp. Med. 193, 483-496 (2001).
68. Valchanova RS, Picard-Maureau M, Budt M, Brune W. Murine cytomegalovirus m142 and m143 are both required to block protein kinase R-mediated shutdown of protein synthesis. J. Virol. 80, 10181-10190 (2006).
69. Budt M, Niederstadt L, Valchanova RS, Jonjic S, Brune W. Specific inhibition of the PKR-mediated antiviral response by the murine cytomegalovirus proteins m142 and m143. J. Virol. 83, 1260-1270 (2009).
70. Steinberg C, Eisenacher K, Gross O et al. The IFN regulatory factor 7-dependent type I IFN response is not essential for early resistance against murine cytomegalovirus infection. Eur. J. Immunol. 39, 1007-1018 (2009).
71. Taylor RT, Bresnahan WA. Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression. J. Virol. 80, 920-928 (2006).
72. Taylor RT, Bresnahan WA. Human cytomegalovirus IE86 attenuates virus- And tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J. Virol. 80, 10763-10771 (2006).
73. Paulus C, Krauss S, Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl Acad. Sci. USA 103, 3840-3845 (2006).
74. Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 78, 10995-11006 (2004).
75. Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc. Natl Acad. Sci. USA 100, 11439-11444 (2003).
76. Krauss S, Kaps J, Czech N, Paulus C, Nevels M. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 83, 12854-12870 (2009).
77. Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J. Virol. 78, 1831-1842 (2004).
78. Abenes G, Lee M, Haghjoo E, Tong T, Zhan X, Liu F. Murine cytomegalovirus open reading frame M27 plays an important role in growth and virulence in mice. J. Virol. 75, 1697-1707 (2001).
79. Cheeseman SH, Rubin RH, Stewart JA et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N. Engl. J. Med. 300, 1345-1349 (1979).
80. Hirsch MS, Schooley RT, Cosimi AB et al. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N. Engl. J. Med. 308, 1489-1493 (1983).
81. Kovarik J, Mayer G, Pohanka E et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 45, 402-405 (1988).
82. Lui SF, Ali AA, Grundy JE, Fernando ON, Griffiths PD, Sweny P. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol. Dial. Transplant. 7, 1230-1237 (1992).
83. Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J. Infect. Dis. 141, 555-562 (1980).
84. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. (2), CD005129 (2007).
85. Bader el-Din NG, Abd el-Meguid M, Tabll AA et al. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virusinfected patients to interferon-based therapy. J. Gastroenterol. Hepatol. 26, 55-62 (2011).
86. Wacheck V, Egorov A, Groiss F et al. A novel type of influenza vaccine: Safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J. Infect. Dis. 201, 354-362 (2010).
87. Honke N, Shaabani N, Cadeddu G et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat. Immunol. 13, 51-57 (2012).
88. Cicin-Sain L, Bubic I, Schnee M et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol. 81, 13825-13834 (2007).
89. Hansen SG, Vieville C, Whizin N et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15, 293-299 (2009).
90. Tsuda Y, Caposio P, Parkins CJ et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. Plos Negl. Trop. Dis. 5, e1275 (2011).
91. Miller DM, Rahill BM, Boss JM et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the JAK/STAT pathway. J. Exp. Med. 187, 675-683 (1998
92. Trilling M, Le VT, Fiedler M, Zimmermann A, Bleifuss E, Hengel H. Identification of DNA-damage DNA-binding protein 1 as a conditional essential factor for cytomegalovirus replication in interferongamma-stimulated cells. Plos Pathog. 7, e1002069 (2011).
93. Kalejta RF, Bechtel JT, Shenk T. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasomedependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell Biol. 23, 1885-1895 (2003).
94. Kaspari M, Tavalai N, Stamminger T, Zimmermann A, Schilf R, Bogner E. Proteasome inhibitor MG132 blocks viral DNA replication and assembly of human cytomegalovirus. FEBS Lett. 582, 666-672 (2008).
95. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57, 33-47 (2006).
96. Aghajan M, Jonai N, Flick K et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 28, 738-742 (2010).
97. Orlicky S, Tang X, Neduva V et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol. 28, 733-737 (2010).
98. Zuo T, Liu D, Lv W et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J. Virol. 86, 5497-5507 (2012).
99. Cristea IM, Moorman NJ, Terhune SS et al. Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early promoter through its interaction with the cellular IFI16 protein. J. Virol. 84, 7803-7814 (2010).
100. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl Acad. Sci. USA 97, 1695-1700 (2000).
101. Jenkins C, Abendroth A, Slobedman B. A novel viral transcript with homology to human interleukin-10 is expressed during latent human cytomegalovirus infection. J. Virol. 78, 1440-1447 (2004).
102. Tan JC, Avdic S, Cao JZ et al. Inhibition of 2',5'-oligoadenylate synthetase expression and function by the human cytomegalovirus ORF94 gene product. J. Virol. 85, 5696-5700 (2011).
103. Cassady KA. Human cytomegalovirus TRS1 and IRS1 gene products block the doublestranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection. J. Virol. 79, 8707-8715 (2005).
104. Hakki M, Marshall EE, De Niro KL, Geballe AP. Binding and nuclear relocalization of protein kinase R by human cytomegalovirus TRS1. J. Virol. 80, 11817-11826 (2006).
105. Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J. Immunol. 162, 6107-6113 (1999).
106. Fliss PM, Jowers TP, Brinkmann MM et al. Viral mediated redirection of NEMO/ IKKgamma to autophagosomes curtails the inflammatory cascade. Plos Pathog. 8, e1002517 (2012).
107. Lembo D, Donalisio M, Hofer A et al. The ribonucleotide reductase R1 homolog of murine cytomegalovirus is not a functional enzyme subunit but is required for pathogenesis. J. Virol. 78, 4278-4288 (2004).
108. Mack C, Sickmann A, Lembo D, Brune W. Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein. Proc. Natl Acad. Sci. USA 105, 3094-3099 (2008).
109. Upton JW, Kaiser WJ, Mocarski ES. Cytomegalovirus M45 cell death suppression requires receptor-interacting protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RIP1. J. Biol. Chem. 283, 16966-16970 (2008).
110. Popkin DL, Watson MA, Karaskov E, Dunn GP, Bremner R, Virgin HW. Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly. Proc. Natl Acad. Sci. USA 100, 14309-14314 (2003).
111. DeFilippis V, Fruh K. Rhesus cytomegalovirus particles prevent activation of interferon regulatory factor 3. J. Virol. 79, 6419-6431 (2005).